- Bulls Stadium, California
- 666-888-0000
- info@example.com
01Dec
Single Arm Trials in HTA: Navigating Assessment Pathways
In the evolving landscape of drug development and regulatory approval, the traditional stronghold of Randomized Controlled Trials (RCTs) is being challenged. The surge in the focus on rare diseases and […]
10Nov
Generating Regulatory-Grade Real-World Evidence: Tools and Frameworks
The integration of real-world evidence (RWE) into the regulatory landscape presents a pivotal shift in the evaluation and assessment of healthcare interventions. Acknowledging the multifaceted challenges in generating high-quality RWE, […]
19Oct
Using Individual Participant Data for Network Meta-Analysis: Advantages and Challenges
The domain of healthcare research has witnessed remarkable advancements in the evaluation of various treatment modalities for specific diseases. One such pioneering approach, the Network Meta-Analysis (NMA), has proven instrumental […]
13Oct
Patient Preference Information (PPI) in Improving Patient-centricity of Healthcare
Patient Preference Information (PPI) has emerged as a powerful tool, gaining recognition in the healthcare industry for its multifaceted ability to enhance patient-centered care, refine clinical trial design, and inform […]
04Oct
Patient Preference Information (PPI) in Healthcare: What is it, and How is it Collected?
In recent years, healthcare has undergone a profound transformation, shifting its focus from traditional, clinician-centric models toward patient-centered care. This shift recognizes that healthcare decisions should not solely revolve around […]
28Sep
Automation in Evidence Synthesis: Are We There Yet?
In the ever-evolving landscape of scientific research and evidence synthesis, the demand for timely, comprehensive, and reliable information has never been greater. Decision-makers, healthcare professionals, and researchers seek up-to-the-minute insights […]
20Sep
Using Synthetic Controls in Oncology Real-World Data Studies for Treatment Insights
In the ever-evolving landscape of healthcare, Real-World Data (RWD) studies have emerged as a pivotal tool in shaping treatment strategies and enhancing patient outcomes. For the Health Economics and Outcomes […]
18Sep
Strategizing Optimal Collection and Use of Real-World Data from Expanded Access Programs
Expanded Access Programs (EAPs) are special programs designed to provide patients with serious or life-threatening conditions access to investigational treatments that have not yet been approved by regulatory authorities, offering […]
11Sep
International Reference Pricing vs. Value-Based Pricing: Drug Pricing Strategies
In the complex landscape of pharmaceutical pricing, two prominent approaches have gained traction: International Reference Pricing (IRP) and Value-Based Pricing (VBP). As nations grapple with the challenge of balancing affordability […]